scispace - formally typeset
M

M. Priglinger

Researcher at Royal North Shore Hospital

Publications -  6
Citations -  4928

M. Priglinger is an academic researcher from Royal North Shore Hospital. The author has contributed to research in topics: Stroke & Modified Rankin Scale. The author has an hindex of 4, co-authored 6 publications receiving 3990 citations.

Papers
More filters
Journal ArticleDOI

Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection

TL;DR: In patients with ischemic stroke with a proximal cerebral arterial occlusion and salvageable tissue on CT perfusion imaging, early thrombectomy with the Solitaire FR stent retriever, as compared with alteplase alone, improved reperfusion, early neurologic recovery, and functional outcome.
Journal ArticleDOI

Penumbral imaging and functional outcome in patients with anterior circulation ischaemic stroke treated with endovascular thrombectomy versus medical therapy: a meta-analysis of individual patient-level data

Bruce C.V. Campbell, +1296 more
- 01 Jan 2019 - 
TL;DR: Estimated ischaemic core volume was independently associated with functional independence and functional improvement but did not modify the treatment benefit of endovascular thrombectomy over standard medical therapy for improved functional outcome.
Journal ArticleDOI

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Graeme J. Hankey, +310 more
- 01 Aug 2020 - 
TL;DR: Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures.
Journal ArticleDOI

Depression but not anxiety predicts recurrent cerebrovascular events

TL;DR: The aim of this study was to define the effect of emotional symptoms on recurrent cerebrovascular events in patients with ischemic stroke.

Endovascular Therapy for Acute Ischemic Stroke: Time to Enter a New Era in Stroke Management

TL;DR: The EXTEND-IA and ESCAPE trials provide the neurointerventional community with a large population of patients in whom rapid, aggressive management is indicated given the demonstrated efficacy of thrombectomy as well as the poor outcome associated with unreperfused large vessel stroke.